Wyeth Alzheimer’s Drug Gets Extra Patent Life Under Court Ruling
Executive Summary
Wyeth's Alzheimer's drug bapineuzumab won an additional eight months of patent coverage under a federal court ruling that found the U.S. Patent and Trademark Office had misinterpreted a law governing agency delays in processing patent applications